MedTrace Logo

Healthy Volunteer Study Comparing Tablet and Capsule Formulations

NCT04001998 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2020-10-30

No results posted yet for this study

Summary

Single center, randomized, open label, two-part crossover study designed to evaluate the PK, food effect, dose proportionality, safety, and tolerability of BLD-2660 in healthy volunteers.

Conditions

Interventions

DRUG

BLD-2660

Randomized to active product

Sponsors & Collaborators

  • Blade Therapeutics

    lead INDUSTRY

Principal Investigators

  • Charlotte Lemech, MD · Scientia Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-28
Primary Completion
2021-06-30
Completion
2021-07-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04001998 on ClinicalTrials.gov